Company news

Sichuan Huiyu Pharmaceutical Co. Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Announcement on Preliminary Earnings Estimate for 2025

February 27, 2026

Announcement on Voluntary Disclosure of Approval of Etoposide Injection and Fluorouracil Injection by the U.S. FDA

February 25, 2026

Announcement on Voluntary Disclosure of Subsidiary Passing On-site Inspection by FDA

February 24, 2026

Announcement on Result of Passive Shareholding Reduction by Shareholder with Over 5% Shares

February 10, 2026

Announcement on Expected Loss in Performance for 2025

January 29, 2026

Announcement on Passive Shareholding Reduction Plan for Shareholders with Over 5% Shares

January 28, 2026

Announcement on Estimated Daily Related Party Transactions in 2026

January 21, 2026

Announcement on Voluntary Disclosure of Clinical Study Cooperation with AstraZeneca

January 9, 2026

Announcement on Obtaining Drug Registration Certificate for Cimetidine Injection

December 23, 2025

Announcement on Progress in Participation in Private Equity Fund Investment and Related Party Transaction

December 19, 2025

Announcement on Obtaining Drug Registration Certificate for Nicardipine Hydrochloride Injection

December 12, 2025

Announcement on Cooperation with Professional Institutions to Invest in the Establishment of a Private Equity Fund

November 27, 2025

Announcement on Voluntary Disclosure of the Acceptance of IND Application for the Drug Combination Involving HYP-6589 Tablets

November 21, 2025

Announcement on Obtaining Drug Registration Certificate for Etoposide Injecton

November 14, 2025

Announcement on Convening the Q3 2025 Performance Briefing

November 6, 2025

Announcement on Participation of the Company and Its Related Parties in Private Equity Fund Investment and Related Party Transaction

October 29, 2025

Announcement on Voluntary Disclosure of Prospective Winning in the National Centralized Drug Procurement

October 28, 2025

Announcement on Judicial and Rotary Freezing of Shares Held by Shareholder with Over 5% Shares

October 10, 2025

Announcement on Progress in Providing Guarantees for Wholly-owned Subsidiary

October 9, 2025

Announcement on Intending to Provide Guarantee for Wholly-owned Subsidiaries

September 26, 2025

Announcement on Rotary Freezing of Partial Shares Held by Shareholder with Over 5% Shares

September 22, 2025

Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025

September 15, 2025

Announcement on Resolutions of the Board of Directors

August 29, 2025

Announcement on the Proposed Signing of a National General Distribution Agreement and Related Party Transactions

August 26, 2025

Announcement on Release of Freezing and Freezing of Partial Shares Held by Shareholder with Over 5% Shares

August 14, 2025

Announcement on Voluntary Disclosure of Administration of the First Subject to the Phase 1 Clinical Trial of HY05350 for Injection

August 4, 2025

Announcement on Voluntary Disclosure of Administration of the First Subject to the Phase 1 Clinical Trial of HY0001a for Injection

July 30, 2025

Announcement on Expiration of Plan of Shareholding Reduction by Shareholder with Over 5% Shares and Results of Shareholding Reduction

July 25, 2025

Announcement on Resolutions of the Board of Supervisors

July 15, 2025

← Newer news releases